Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seeking Alpha • Dec 2, 2025

Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Nov 26, 2025

Revvity, Inc. (RVTY) Presents at Jefferies London Healthcare Conference 2025 Transcript

Revvity, Inc. ( RVTY ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Presentation Tycho Peterson Jefferies LLC, Research Division Okay. Thank you.

Seeking Alpha • Nov 18, 2025

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals' solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce.

Business Wire • Nov 10, 2025

Revvity, Inc. (RVTY) Presents at UBS Global Healthcare Conference 2025 Transcript

Revvity, Inc. ( RVTY ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division Good morning, everybody, and thank you all for joining us for 8 a.m. session with Revvity.

Seeking Alpha • Nov 10, 2025

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative. The Somatic Reference Samples (SRS) Initiative is a public-private partnership convened and led by MDIC to guide the development of reference samples that can b.

Business Wire • Nov 10, 2025

Revvity Analysts Increase Their Forecasts After Q3 Earnings

Revvity, Inc. (NYSE:RVTY) announced mixed third-quarter 2025 financial results on Monday.

Benzinga • Oct 28, 2025

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu.

Business Wire • Oct 28, 2025

Revvity lifts annual profit forecast on renewed demand in diagnostics unit

Medical equipment maker Revvity on Monday raised its annual profit forecast and beat third-quarter estimates on improving demand for its testing kits in the diagnostics unit.

Reuters • Oct 27, 2025

Revvity, Inc. (RVTY) Q3 2025 Earnings Call Transcript

Revvity, Inc. (NYSE:RVTY ) Q3 2025 Earnings Call October 27, 2025 8:00 AM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Prahlad Singh - CEO, President & Director Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Michael Ryskin - BofA Securities, Research Division Daniel Leonard - UBS Investment Bank, Research Division Tycho Peterson - Jefferies LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Q3 2025 Revvity Earnings Conference Call.

Seeking Alpha • Oct 27, 2025